Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spanish bioscience R&D, features coronary DES and 26 Dx techs:

This article was originally published in Clinica

Executive Summary

A drug-eluting coronary stent features in a survey of leading bioscientific R&D projects currently underway in Spain. According to the national bio-enterprise association ASEBIO, which performed the survey, the stent being developed by Barcelona-based Palau Pharma - one of 19 biotechnology companies engaged in pharmaceutical R&D - is now at phase III trial stage. A total of 119 human healthcare R&D projects are reported in the survey, of which 26 relate specifically to diagnostic/prognostic technologies. The leading clinical areas for diagnostic and medtech-related research, according to ASEBIO, are: oncology (32%), infectious diseases (22%) and cardiovascular disease (14%). The study will serve to inform the fourth bi-annual BioSpain international bioscience convention, which takes place during September 17-18 2008, in Granada.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT046778

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel